Widely used:Recently Viewed
Clear AllQuality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$1,254 Mln
Revenue (TTM)
$537 Mln
Net Profit (TTM)
$0 Mln
ROE
0.3 %
ROCE
-- %
P/E Ratio
6.1
P/B Ratio
1.7
Industry P/E
--
EV/EBITDA
2.9
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$0.9
Face value
--
Shares outstanding
225,159,008
CFO
€-920.37 Mln
EBITDA
€-1,127.52 Mln
Net Profit
€-1,215.77 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
CureVac NV (CVAC)
| 61.0 | 47.6 | 78.8 | 57.8 | -27.3 | -- | -- |
|
BSE Sensex
| 4.1 | -1.1 | 9.8 | 5.8 | 16.6 | 19.4 | 11.7 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
|---|---|---|---|
|
CureVac NV (CVAC)
| -30.2 | -82.4 | -57.7 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
CureVac NV (CVAC)
|
5.5 | 1,254.1 | 537.3 | 200.0 | 48.5 | 28.1 | 6.1 | 1.7 |
| 0.2 | 3.0 | 0.9 | -70.0 | -7,823.0 | -241.9 | -- | 0.1 | |
| 0.3 | 9.4 | 48.5 | -35.5 | -117.5 | 397.6 | -- | 0.9 | |
| 0.8 | 53.1 | 0.1 | -44.7 | -35,719.4 | -65.9 | -- | 0.7 | |
| 1.3 | 34.5 | 5.2 | -28.0 | -451.1 | -95.4 | -- | 1.3 | |
| 16.6 | 924.2 | 0.0 | -141.0 | -- | -49.9 | -- | 3.5 | |
| 1.9 | 198.0 | 19.0 | -30.2 | -157.4 | -58.1 | -- | 2.2 |
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). The company's portfolio includes clinical and preclinical candidates for various disease indications in... prophylactic vaccines, oncology, and molecular therapy. It also delivers optimized mRNAs to stimulate the production of therapeutic proteins utilizing its technology and instructs human cells to produce or secrete specific proteins in the nucleus, cytoplasm, cellular organelles, and cell membrane. In addition, the company offers The RNA Printer, a downsized, integrated, and highly automated process for manufacturing of mRNA vaccines and therapeutics. Further, it develops prophylactic vaccine lead candidate that addresses urinary tract infections targeting uropathogenic E. coli (UPEC) bacteria; vaccine candidates CV0601 and CV0701, which are in phase 2 clinical study against SARS-CoV-2; vaccines for off-the-shelf and fully personalized cancer precision immunotherapies in oncology; and CVGBM for treating cancer. Additionally, the company develops, manufactures, and commercializes mRNA vaccines targeting SARS-CoV-2 variants; antigen cancer precision immunotherapy candidate that targets squamous non-small cell lung cancer; and antigen cancer precision immunotherapy candidate CVGBM that is tested in patients with surgically resected MGMT-unmethylated glioblastoma or astrocytoma with a molecular signature of glioblastoma. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany. Address: Friedrich-Miescher-Strasse 15, Tübingen, Germany, 72076 Read more
MD, CFO & Member of Management Board
Mr. Pierre Kemula B.Sc.
MD, CFO & Member of Management Board
Mr. Pierre Kemula B.Sc.
Headquarters
Tübingen
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of CureVac NV (CVAC) stood at $ 921 Mln as on 31-Mar-25
The share price of CureVac NV (CVAC) is $5.49 (NASDAQ) as of 18-Jun-2025 16:00 EDT. CureVac NV (CVAC) has given a return of -27.27% in the last 3 years.
CureVac NV (CVAC) has a market capitalisation of $ 1,254 Mln as on 17-Jun-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of CureVac NV (CVAC) is 1.66 times as on 17-Jun-2025, a 75% discount to its peers’ median range of 6.66 times.
The P/E ratio of CureVac NV (CVAC) is 6.07 times as on 17-Jun-2025.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the CureVac NV (CVAC) and enter the required number of quantities and click on buy to purchase the shares of CureVac NV (CVAC).
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). The company's portfolio includes clinical and preclinical candidates for various disease indications in prophylactic vaccines, oncology, and molecular therapy. It also delivers optimized mRNAs to stimulate the production of therapeutic proteins utilizing its technology and instructs human cells to produce or secrete specific proteins in the nucleus, cytoplasm, cellular organelles, and cell membrane. In addition, the company offers The RNA Printer, a downsized, integrated, and highly automated process for manufacturing of mRNA vaccines and therapeutics. Further, it develops prophylactic vaccine lead candidate that addresses urinary tract infections targeting uropathogenic E. coli (UPEC) bacteria; vaccine candidates CV0601 and CV0701, which are in phase 2 clinical study against SARS-CoV-2; vaccines for off-the-shelf and fully personalized cancer precision immunotherapies in oncology; and CVGBM for treating cancer. Additionally, the company develops, manufactures, and commercializes mRNA vaccines targeting SARS-CoV-2 variants; antigen cancer precision immunotherapy candidate that targets squamous non-small cell lung cancer; and antigen cancer precision immunotherapy candidate CVGBM that is tested in patients with surgically resected MGMT-unmethylated glioblastoma or astrocytoma with a molecular signature of glioblastoma. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany. Address: Friedrich-Miescher-Strasse 15, Tübingen, Germany, 72076
The CEO & director of Mr. Pierre Kemula B.Sc.. is CureVac NV (CVAC), and CFO & Sr. VP is Mr. Pierre Kemula B.Sc..
There is no promoter pledging in CureVac NV (CVAC).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
105
|
|
|
36
|
|
|
15
|
|
|
4
|
|
|
3
|
|
|
1
|
|
|
105
|
|
|
36
|
|
|
15
|
| CureVac NV (CVAC) | Ratios |
|---|---|
|
Return on equity(%)
|
28.14
|
|
Operating margin(%)
|
48.47
|
|
Net Margin(%)
|
37.22
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of CureVac NV (CVAC) was $0 Mln.
$-0.01
(
